Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Cleveland Diagnostics, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Cleveland Diagnostics, Inc.

Regulatory records
2
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 2 FDA records to the applicant name Cleveland Diagnostics, Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Nov 28, 2025 to Jul 28, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code QRF appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P200048, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 3615 Superior Ave., Suite 4407b, Cleveland, OH, 44114. Recorded on P200048/S001, decision dated Jul 28, 2026.

Changes described in PMA records

P200048/S001: IsoPSA Assay

FDA’s recorded scope: extension of the shelf-life of the IsoPSA Controls

Jul 28, 2026 · Real-Time Process

P200048: IsoPSA Assay

FDA’s recorded scope: Approval for the IsoPSA Assay.The IsoPSA Assay is an in vitro test system that combines the results of total Prostate Specific Antigen (PSA) (Elecsys, Roche Diagnostics) and free PSA (Elecsys, Roche Diagnostics) from partitioned heparinized plasma into a single numerical index. The IsoPSA Assay is indicated for use in conjunction with other patient information to aid in detection of high-grade prostate cancer (Grade Group >= 2; Gleason score >= 7) in men >= 50 years of age, with total PSA levels >= 4.0 to =< 10.0 ng/mL for whom a biopsy is being considered by a urologist based on current standard of care, before consideration of IsoPSA Assay results.Prostatic biopsy is required for the diagnosis of cancer.

Nov 28, 2025

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
IsoPSA AssayP200048/S001
Cleveland Diagnostics, Inc.PMA supplementJul 28, 2026FDA
Cleveland Diagnostics, Inc.PMA approvalNov 28, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.